Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers

ConclusionTNHH was well-tolerated following IV infusion. The pharmacokinetic and pharmacodynamic characteristics of TNHH indicate that it merits clinical trials. It is recommended that the single dose of TNHH should be 1.0  mg/kg in future studies, and the expected effect may be achieved after 5–7 days of continuous administration.Trial RegistrationThe study is registered athttp://www.chictr.org.cn as ChiCTR-TQR-14004752.
Source: CNS Drugs - Category: Neurology Source Type: research